Be The Match BioTherapies

54 employees

Be The Match BioTherapies® is built on the foundation established by our parent company.

Investor insights

Sectors invested in

Therapeutics5

Biotechnology5

Manufacturing3

Genetics3

Health Care3

Autoimmune Diseases2

Transplant Medicine2

Medical2

Hematopoietic Stem Cell Biology2

Blood Disorders2

Funding rounds participated in

$52M sweet spot round size

Most of their 5 investments are in rounds between $35M and $75M

Basic info

Industry

biotechnology research

Sectors

cell therapy patient outcomes

collection site qualification

cryopreserved cells

cell therapy supply chain

cell sourcing

cell therapy delivery

supply chain case management

quality system audit

clinical trial design

clinical trial recruitment

cell therapy source material

consented cell donors

cell therapy clinical trial network

custom search algorithm

MatchSource software

apheresis starting material

cell therapy transport

collection network development

bioinformatics

cell therapy logistics documentation

cell therapy logistics

FDA requirements for cell therapy

be the match registry

cell therapy customs requirements

cell therapy starting material

cell therapy clinical research

cord blood for cell therapy

HapLogic

Date founded

2016

Investments made

Tmunity Therapeutics Incorporated raised $75M on October 31, 2019

Investors: Westlake Village BioPartners®, Gilead Sciences, Andreessen Horowitz and Be The Match BioTherapies

Tmunity Therapeutics Incorporated raised $35M on April 19, 2018

Investors: Parker Institute for Cancer Immunotherapy, Lilly Asia Ventures, Gilead Sciences, PingAn Ventures, University of Pennsylvania, Kleiner Perkins and Be The Match BioTherapies

Magenta Therapeutics raised $52M on April 9, 2018

Investors: Access Industries, Eventide Asset Management, Casdin Capital, LLC and Be The Match BioTherapies

Tmunity Therapeutics Incorporated raised $100M on January 23, 2018

Investors: Parker Institute for Cancer Immunotherapy, Lilly Asia Ventures, Gilead Sciences, University of Pennsylvania, PingAn Ventures and Be The Match BioTherapies

Magenta Therapeutics raised $50M on May 2, 2017

Investors: Access Industries, GV, Third Rock Ventures, Partners HealthCare, Casdin Capital, LLC, Atlas Venture and Be The Match BioTherapies